New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
07:02 EDTMGNXCMC Biologics and MacroGenics enter masters services agreement
CMC Biologics and MacroGenics have entered into a Master Services Agreement for process validation activities and clinical manufacturing of another of MacroGenics' oncology product candidates.
News For MGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
16:18 EDTMGNXMacroGenics' leukemia candidate shows positive results in nonclinical paper
MacroGenics announced the publication of a nonclinical research paper on MGD006 in Science Translational Medicine. MGD006 is a humanized, Dual-Affinity Re-Targeting molecule that recognizes both CD123 and CD3. CD123, the Interleukin-3 receptor alpha chain, is expressed on malignant cells, including leukemic stem cells, in acute myeloid leukemia and other hematological diseases. The recently published research shows anticancer activity in vitro and in mouse models together with favorable pharmacodynamic and safety profile in nonhuman primates. The paper describes how MacroGenics' scientists engineered the MGD006 DART and demonstrated in vitro that the molecule can arm T cells from AML patients to reduce blast counts and is effective in eliminating AML cells implanted in mice.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use